{
  "success": true,
  "message": "Success",
  "data": {
    "info": "\ufeff<div style=\"font-size: 14px; font-family: 'Roboto', sans-serif; text-align: justify; line-height: 1.6;\">\r\n\t<img src=\"http://cache2.globedr.com/System/VaccineImage/en-US/Hib.jpg\" alt=\"Hib disease\" width=\"100%\" />\r\n\t<br />\r\n\t<p><strong>1. Information</strong>\r\n\t</p>\r\n\t<p style=\"padding-left: 15px\">\r\n\t\t<strong>Hib vaccine </strong>prevents serious infections caused by a type of bacteria called Haemophilus influenzae type b. Such infections include meningitis (an infection of the covering of the brain and spinal cord), pneumonia (lung infection), and epiglottitis (a severe throat infection).<br />\r\n\t\tHib vaccine is recommended for all children under five years old in the United States, and it is usually given to infants starting at two months old. The Hib vaccine can be combined with other vaccines. Some brands of vaccine contain Hib along with other vaccines in a single shot.<br />\r\n\t\t<strong>Disease spread by: </strong>Air, direct contact<br />\r\n\t\t<strong>Disease symptoms: </strong>May be no symptoms unless bacteria enter the blood<br />\r\n\t\t<strong>Disease complications: </strong>Meningitis (infection of the covering around the brain and spinal cord), intellectual disability, epiglottitis (life-threatening infection that can block the windpipe and lead to serious breathing problems), pneumonia (infection in the lungs), death.<br />\r\n\t</p>\r\n\t<p><strong>2. Preventive measures</strong>\r\n\t</p>\r\n\t<div style=\"padding-left: 15px\">\r\n\t\tHaemophilus influenzae type b (Hib) conjugate vaccine.<br />\r\n\t\t(Minimum age: 6 weeks for PRP-T [ActHIB, DTaP-IPV/Hib (Pentacel), Hiberix, and Hib-MenCY (MenHibrix)], PRPOMP [PedvaxHIB])<br />\r\n\t\tCatch-up vaccination:<br />\r\n\t\t<ul style=\"margin: 0\">\r\n\t\t\t<li>If dose 1 was administered at ages 12 through 14 months, administer a second (final) dose at least 8 weeks after dose 1, regardless of Hib vaccine used in the primary series.</li>\r\n\t\t\t<li>If both doses were PRP-OMP (PedvaxHIB or COMVAX) and were administered before the first birthday, the third (and final) dose should be administered at age 12 through 59 months and at least 8 weeks after the second dose.</li>\r\n\t\t\t<li>If the first dose was administered at age 7 through 11 months, administer the second dose at least 4 weeks later and a third (and final) dose at age 12 through 15 months or 8 weeks after second dose, whichever is later.</li>\r\n\t\t\t<li>If first dose is administered before the first birthday and second dose administered at younger than 15 months, a third (and final) dose should be administered 8 weeks later.</li>\r\n\t\t\t<li>For unvaccinated children aged 15â€“59 months, administer only 1 dose.</li>\r\n\t\t</ul>\r\n\t</div>\r\n</div>"
  },
  "errors": null
}